{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:40:08Z","timestamp":1742733608222,"version":"3.40.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Bayer Healthcare Company Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12325-025-03131-9","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T02:03:46Z","timestamp":1740708226000},"page":"1881-1891","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Application of a Value Framework to Determine the Value of Prophylaxis Versus On-Demand Treatment in Adults with Hemophilia\u00a0A in China"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7339-5101","authenticated-orcid":false,"given":"Baoying","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7667-8294","authenticated-orcid":false,"given":"Ailing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1589-6636","authenticated-orcid":false,"given":"Rong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1911-4245","authenticated-orcid":false,"given":"Lu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5130-4835","authenticated-orcid":false,"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6240-695X","authenticated-orcid":false,"given":"Shanlian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4800-4935","authenticated-orcid":false,"given":"Jianwei","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"Suppl 6","key":"3131_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"1","key":"3131_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47.","journal-title":"Haemophilia"},{"key":"3131_CR3","unstructured":"National Health Commission of the People\u2019s Republic of China. Diagnosis and treatment guidelines for hemophilia\u00a0A (2022 Edition). Clin Educ Gen Pract. 2022;20(07):579\u201383."},{"issue":"6","key":"3131_CR4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1046\/j.1351-8216.2003.00826.x","volume":"9","author":"L Zhang","year":"2003","unstructured":"Zhang L, Li H, Zhao H, Zhang X, Ji L, Yang R. Retrospective analysis of 1312 patients with haemophilia and related disorders in a single Chinese institute. Haemophilia. 2003;9(6):696\u2013702.","journal-title":"Haemophilia"},{"issue":"02","key":"3131_CR5","first-page":"89","volume":"22","author":"F Xue","year":"2023","unstructured":"Xue F, Dai J, Chen LX, et al. Report on diagnosis and treatment of hemophilia in China 2023. J Diagn Concepts Pract. 2023;22(02):89\u2013115.","journal-title":"J Diagn Concepts Pract"},{"issue":"04","key":"3131_CR6","first-page":"265","volume":"41","author":"Hemophilia Treatment Center Collaborative Network of China","year":"2020","unstructured":"Hemophilia Treatment Center Collaborative Network of China. Chinese guidelines on the treatment of hemophilia (version 2020). Chin J Hematol. 2020;41(04):265\u201371.","journal-title":"Chin J Hematol"},{"issue":"1","key":"3131_CR7","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1111\/hae.14217","volume":"27","author":"X Song","year":"2021","unstructured":"Song X, Zhong J, Xue F, et al. An overview of patients with haemophilia\u00a0A in China: epidemiology, disease severity and treatment strategies. Haemophilia. 2021;27(1):e51\u20139.","journal-title":"Haemophilia"},{"issue":"11","key":"3131_CR8","first-page":"130","volume":"35","author":"LR Yue","year":"2022","unstructured":"Yue LR, Zhang ZZ, Zhang YL, Lu QY, Yao NL. The international experience and enlightenment of value-based payment for basic medical insurance. Med Soc. 2022;35(11):130\u20134.","journal-title":"Med Soc"},{"key":"3131_CR9","doi-asserted-by":"crossref","unstructured":"Langley PC. Nonsense on stilts\u2014part 1: the ICER 2020\u20132023 value assessment framework for constructing imaginary worlds. Innov Pharm. 2020;11(1):10.24926\/iip.v11i1.2444.","DOI":"10.24926\/iip.v11i1.2444"},{"issue":"2","key":"3131_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2017.12.009","volume":"21","author":"LP Garrison Jr","year":"2018","unstructured":"Garrison LP Jr, Neumann PJ, Willke RJ, et al. A health economics approach to US value assessment frameworks-summary and recommendations of the ISPOR Special Task Force Report [7]. Value Health. 2018;21(2):161\u20135.","journal-title":"Value Health"},{"key":"3131_CR11","unstructured":"Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital, National Rare Disease Committee. Expert consensus on the application of multi-criteria decision analysis in clinical comprehensive evaluation of orphan drugs (2022). Med J Peking Union Med Coll Hosp. 2022;1(02):158\u201377."},{"issue":"5","key":"3131_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/hae.14603","volume":"28","author":"X He","year":"2022","unstructured":"He X, Wang X, Dong C, Zhao M, Wu J. The long-term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia\u00a0A in China: population-based predictions from 2018 to 2033. Haemophilia. 2022;28(5):726\u201336.","journal-title":"Haemophilia"},{"issue":"6","key":"3131_CR13","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/hae.13456","volume":"24","author":"B O\u2019Mahony","year":"2018","unstructured":"O\u2019Mahony B, Dolan G, Nugent D, Goodman C. Patient-centred value framework for haemophilia. Haemophilia. 2018;24(6):873\u20139.","journal-title":"Haemophilia"},{"issue":"5","key":"3131_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/hae.13589","volume":"24","author":"D Nugent","year":"2018","unstructured":"Nugent D, O\u2019Mahony B, Dolan G. Value of prophylaxis vs on-demand treatment: application of a value framework in hemophilia. Haemophilia. 2018;24(5):755\u201365.","journal-title":"Haemophilia"},{"issue":"Suppl 2","key":"3131_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/hae.14511","volume":"28","author":"MW Skinner","year":"2022","unstructured":"Skinner MW, Dolan G, Eichler H, O\u2019Mahony B. A preliminary application of a haemophilia value framework to emerging therapies in haemophilia. Haemophilia. 2022;28(Suppl 2):9\u201318.","journal-title":"Haemophilia"},{"issue":"04","key":"3131_CR16","first-page":"61","volume":"42","author":"AL Lin","year":"2023","unstructured":"Lin AL, Tan BY, Xuan JW, Hu SL. A review on the multidimensional value of prophylactic treatment in adult hemophilia\u00a0A patients. Chin Health Econ. 2023;42(04):61\u20134.","journal-title":"Chin Health Econ"},{"issue":"1","key":"3131_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","volume":"19","author":"P Thokala","year":"2016","unstructured":"Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making\u2014an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19(1):1\u201313.","journal-title":"Value Health"},{"key":"3131_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12911-015-0234-7","volume":"15","author":"K Schmidt","year":"2015","unstructured":"Schmidt K, Aumann I, Hollander I, Damm K, von der Schulenburg JM. Applying the analytic hierarchy process in healthcare research: a systematic literature review and evaluation of reporting. BMC Med Inform Decis Mak. 2015;15:112.","journal-title":"BMC Med Inform Decis Mak"},{"key":"3131_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.869319","volume":"13","author":"C Zhang","year":"2022","unstructured":"Zhang C, Ma EL, Liu BL, Wu B, Gu ZC, Lin HW. Framework development for clinical comprehensive evaluation of drugs\u2014a study protocol using the Delphi method and analytic hierarchy process. Front Pharmacol. 2022;13: 869319.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3131_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40261-021-01108-4","volume":"42","author":"G Gourzoulidis","year":"2022","unstructured":"Gourzoulidis G, Stefanou G, Economou M, et al. Application of multicriteria decision analysis to determine the value of prophylaxis relative to on-demand treatment in hemophilia A and emicizumab versus replacement therapy in the Greek healthcare setting. Clin Drug Investig. 2022;42(1):75\u201385.","journal-title":"Clin Drug Investig"},{"issue":"04","key":"3131_CR21","first-page":"468","volume":"1","author":"SP Li","year":"2022","unstructured":"Li SP, Dou L, Fang YH. Current situation and prospect of pharmacoeconomic evaluation of hemophilia in China. J Rare Dis. 2022;1(04):468\u201373.","journal-title":"J Rare Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03131-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03131-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03131-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:09:35Z","timestamp":1742731775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03131-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3131"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03131-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"13 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rong Han and Lu Bai are employees of Bayer Healthcare Company Ltd. Shanlian Hu, Jianwei Xuan, Baoying Tan, Ailing Lin, and Jing Sun state that they had no interests that might be perceived as posing a conflict or bias.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"In accordance with the ethical review requirements of the Chinese government and Bayer\u2019s Standard Operating Procedures (SOP), the stakeholder survey did not involve the collection or recording of biological samples or medical data from patients and therefore did not require ethics committee review. All stakeholders provided informed consent to participate and agreed to the publication of their responses in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}